These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24308040)

  • 1. In the literature. Piperacillin-tazobactam and extended-spectrum β-lactamase--producing Escherichia coli.
    Clin Infect Dis; 2013 Nov; 57(10):iii-iv. PubMed ID: 24308040
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.
    Liu Q; Rand K; Derendorf H
    Int J Antimicrob Agents; 2004 May; 23(5):494-7. PubMed ID: 15120729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam.
    Peterson LR
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():181-4. PubMed ID: 18154544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates.
    Lee J; Oh CE; Choi EH; Lee HJ
    Int J Infect Dis; 2013 Aug; 17(8):e638-43. PubMed ID: 23523562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro efficacy of ceftriaxone/sulbactam against Escherichia coli isolates producing CTX-M-15 extended-spectrum beta-lactamase.
    Shahid M; Singhai M; Malik A; Shukla I; Khan HM; Shujatullah F; Tahira F
    J Antimicrob Chemother; 2007 Jul; 60(1):187-8. PubMed ID: 17491002
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species.
    Gavin PJ; Suseno MT; Thomson RB; Gaydos JM; Pierson CL; Halstead DC; Aslanzadeh J; Brecher S; Rotstein C; Brossette SE; Peterson LR
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2244-7. PubMed ID: 16723596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam.
    Pitout JD; Le P; Church DL; Gregson DB; Laupland KB
    Int J Antimicrob Agents; 2008 Oct; 32(4):333-8. PubMed ID: 18701262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of antibiotic utilization measures and reduced incidence of infections with extended-spectrum beta-lactamase-producing organisms.
    Lan CK; Hsueh PR; Wong WW; Fung CP; Lau YT; Yeung JY; Young GT; Su CC
    J Microbiol Immunol Infect; 2003 Sep; 36(3):182-6. PubMed ID: 14582562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of imipenem-cilastatin, ertapenem, piperacillin-tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice.
    Pultz MJ; Donskey CJ
    Antimicrob Agents Chemother; 2007 Aug; 51(8):3044-5. PubMed ID: 17562802
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of cefepime for the treatment of infections caused by extended spectrum: beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Arya SC; Agarwal N; Solanki BS; Agarwal S
    Singapore Med J; 2007 Jun; 48(6):600-1. PubMed ID: 17538771
    [No Abstract]   [Full Text] [Related]  

  • 12. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.
    Petrikkos G; Markogiannakis A; Papaparaskevas J; Daikos GL; Stefanakos G; Zissis NP; Avlamis A
    Int J Antimicrob Agents; 2007 Jan; 29(1):34-8. PubMed ID: 17189092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro efficiency of the piperacillin/tazobactam combination against inhibitor-resistant TEM- and complex mutant TEM-producing clinical strains of Escherichia coli.
    Robin F; Krebs M; Delmas J; Gibold L; Mirande C; Bonnet R
    J Antimicrob Chemother; 2011 May; 66(5):1052-6. PubMed ID: 21393211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-spectrum β-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests.
    Marchaim D; Sunkara B; Lephart PR; Gudur UM; Bhargava A; Mynatt RP; Zhao JJ; Bheemreddy S; Hayakawa K; Chopra T; Dhar S; Kaye KS
    Infect Control Hosp Epidemiol; 2012 Aug; 33(8):853-5. PubMed ID: 22759556
    [No Abstract]   [Full Text] [Related]  

  • 15. Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Bishara J; Livne G; Ashkenazi S; Levy I; Pitlik S; Ofir O; Lev B; Samra Z
    Isr Med Assoc J; 2005 May; 7(5):298-301. PubMed ID: 15909461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli.
    Retamar P; López-Cerero L; Muniain MA; Pascual Á; Rodríguez-Baño J;
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3402-4. PubMed ID: 23612190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for infection or colonization with CTX-M extended-spectrum-β-lactamase-positive Escherichia coli.
    Han JH; Kasahara K; Edelstein PH; Bilker WB; Lautenbach E
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5575-80. PubMed ID: 22890772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.
    Docobo-Pérez F; López-Cerero L; López-Rojas R; Egea P; Domínguez-Herrera J; Rodríguez-Baño J; Pascual A; Pachón J
    Antimicrob Agents Chemother; 2013 May; 57(5):2109-13. PubMed ID: 23439636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Thomson KS; Moland ES
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3548-54. PubMed ID: 11709338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the risk of acquiring in vitro resistance to doripenem and tazobactam/piperacillin by CTX-M-15-producing Escherichia coli.
    Horiyama T; Kanazawa S; Hara T; Izawa M; Sato T; Yamaguchi T; Tsuji M; Maki H
    J Infect Chemother; 2015 May; 21(5):381-4. PubMed ID: 25662788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.